Glioma development is an extremely complex process with changes occurring in numerous genes. HOXD antisense growthassociated long noncoding RNA (HOXD-AS1), an important long noncoding RNA (lncRNA), is known to regulate metastasisrelated gene expression in bladder cancer, ovarian cancer and neuroblastoma. Here, we elucidated the function and possible molecular mechanisms of lncRNA HOXD-AS1 in human glioma cells. Our results proved that HOXD-AS1 expression was upregulated in glioma tissues and in glioma cell lines. HOXD-AS1 overexpression promoted cell migration and invasion in vitro, whereas knockdown of HOXD-AS1 expression repressed these cellular processes. Mechanistic studies further revealed that HOXD-AS1 could compete with the transcription factor E2F8 to bind with miR-130a, thus affecting E2F8 expression. Additionally, reciprocal repression was observed between HOXD-AS1 and miR-130a, and miR-130a mediated the tumor-suppressive effects of HOXD-AS1 knockdown. Taken together, these results provide a comprehensive analysis of the role of HOXD-AS1 in glioma cells and offer important clues to understand the key roles of competing endogenous RNA (ceRNA) mechanisms in human glioma.
Glioma development is an extremely complex process with changes occurring in numerous genes. HOXD antisense growthassociated long noncoding RNA (HOXD-AS1), an important long noncoding RNA (lncRNA), is known to regulate metastasisrelated gene expression in bladder cancer, ovarian cancer and neuroblastoma. Here, we elucidated the function and possible molecular mechanisms of lncRNA HOXD-AS1 in human glioma cells. Our results proved that HOXD-AS1 expression was upregulated in glioma tissues and in glioma cell lines. HOXD-AS1 overexpression promoted cell migration and invasion in vitro, whereas knockdown of HOXD-AS1 expression repressed these cellular processes. Mechanistic studies further revealed that HOXD-AS1 could compete with the transcription factor E2F8 to bind with miR-130a, thus affecting E2F8 expression. Additionally, reciprocal repression was observed between HOXD-AS1 and miR-130a, and miR-130a mediated the tumor-suppressive effects of HOXD-AS1 knockdown. Taken together, these results provide a comprehensive analysis of the role of HOXD-AS1 in glioma cells and offer important clues to understand the key roles of competing endogenous RNA (ceRNA) mechanisms in human glioma.
Glioma is the most common and aggressive form of primary brain tumors, accounting for 80% of primary malignant brain tumors of all tumors. Glioblastoma multiforme (GBM) is the most aggressive type of glioma, with a median survival of 15 months following standard treatment. 1 The current multimodal treatment regimen-including surgical resection, concurrent chemo-irradiation and adjuvant temozolomidehas yielded significant improvement in the patient survival. 2, 3 However, glioma invasion makes it difficult to be completely removed, resulting in relapse and death in patients with malignant glioma. Therefore, elucidation of the molecular mechanisms underlying glioma maintenance and development of novel and effective strategies for the early diagnosis and treatment of glioma are urgently needed. Long noncoding RNAs (lncRNAs) are defined as ncRNAs of >200 nucleotides in length. 4 In recent years, with the establishment of new bioinformatics and experimental strategies, a large number of novel lncRNA transcripts have been identified. 5 LncRNAs play an important role in both transcriptional and post-transcriptional processes. 6 Two molecular mechanisms of lncRNA in glioma development have been suggested. 7, 8 Previous studies have demonstrated that lncRNAs regulated downstream signaling pathways by binding to specific proteins, 9 while Hajernis et al. suggested that lncRNAs regulated downstream signaling pathways by binding to miRNAs. 10 LncRNAs have been shown to form a competing endogenous RNA (ceRNA) network of RNA crosstalk by acting as molecular sponges for microRNAs (miRNAs), [11] [12] [13] [14] thereby modulating their gene repressive activity. 15, 16 In the competing mechanism, lncRNA compete for the same pool of miRNA with specific mRNAs, thereby desuppressing the mRNAs. 17, 18 Sponges encompass different RNAs competing with each other to attract miRNAs for interactions and exert their decoy activity by recruiting miRNA molecules via basepairing with miRNA-recognition elements (MREs). [19] [20] [21] This ceRNA activity implicates a novel function of lncRNAs, and its perturbation might have consequences in pathological conditions in glioma. [22] [23] [24] [25] Understanding the role of cancerassociated lncRNAs would reveal new perspectives regarding the mechanisms of tumor progression.
LncRNA HOXD-AS1 is transcribed from the HOXD cluster on human chromosome 2q31.2 in an antisense manner 26 and it is upregulated in ovarian cancer, bladder cancer and breast cancer. [27] [28] [29] HOXD-AS1 is induced by retinoic acid (RA), and regulated by PI3K/Akt signaling pathway. 27 It controls genes that are implicated in RA-mediated cell differentiation, as well as angiogenesis and inflammation, which are hallmarks of metastasized cancer. [30] [31] [32] However, the expression and function of HOXD-AS1 lncRNA in glioma cells was largely unknown. Hence, in this study, we used paired normal samples from epilepsy patients and cancerous samples from glioma specimens to discover the upregulation of HOXD-AS1 transcript levels. Bioinformatics analysis predicted that miR-130a mediated this process and confirmed the expression relationship between HOXD-AS1, miR130a and the transcription factor E2F8. These results provided new insights into the molecular functions of HOXD-AS1 and its potential as a prognostic factor and therapeutic target in glioma.
Materials and Methods
Human tissue specimens and cell culture Total RNA was extracted from the glioma specimens as described above. The RNA concentration and quality was measured using NanoDrop 2000 (Thermo Fisher Scientific) to ensure sample effectiveness. The first strand of cDNA was synthesized using a SMARTer TM RACE cDNA Amplification Kit (Clontech Laboratories, USA) according to the manufacturer's instructions. Two pairs of specific primers were designed against the known sequences of HOXD-AS1 in the 5 0 and 3 0 ends. One pair of specific primers was designed at 300 bp as the outer primer, and another was designed at 200 bp as the inner primer. Using the first-strand of cDNA as the template, the high specificity of 5 0 and 3 0 cDNA fragments was obtained by a nested-PCR method. Also using the first-strand cDNA as the template, the first round PCR was carried out with the outer primer, and after electrophoresis, the gel was cut according to the product length. The second round of PCR was carried out with the inner primer, using the first round of PCR products as the templates. After nucleic acid electrophoresis, the PCR products of interest were extracted from the gel. The PCR products were then cloned into a vector using the pGM-T cloning kit (TIAN-GEN Biotech, Beijing, China) and they were transformed into chemically competent TOP10 Escherichia coli cells (Invitrogen, USA). Individual colonies were cultured and plasmids were purified using a QIAprep Spin Miniprep Kit (Qiagen What's new? Glioblastoma is one of the deadliest human cancers, and early diagnostic markers and new therapies are urgently needed. Here the authors found a long-noncoding RNA, HOXD-AS1, upregulated in human glioma. HOXD-AS1 is transcribed from the HOXD gene cluster in an antisense fashion and promoted glioma cell migration and invasion, a process reversed by the transcription factor E2F8. These results provide new mechanistic insight into glioma development and might help define new diagnostics or treatments for glioblastoma patients.
Inc., Chatsworth, CA, USA). Sequencing was performed by JIELI Biology (Shanghai, China). The genomic sequences were confirmed using BLAST at the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih. gov/gorf/gorf.html) and they were analyzed using DNAMAN software (http://www.lynnon.com/pc/framepc.html).
Lentivirus vector construction, infection and siRNA transfection
The full-length human lncRNA HOXD-AS1 was ligated into the pSPT-CMV-GFP-DOX vector (Roche). Virus particles were harvested at 48 hr after cotransfection of the lentiviral vector (or the control lentivirus vector) with the packaging vectors into HEK293T cells using Lipofectamine 2000 (Life Technologies Corporation, USA). The U87 cells were then infected with the lentivirus or the control virus (NC). Doxycycline (dox; Santa Cruz, Dallas, USA) was used to induce HOXD-AS1 and GFP expression. GFP-positive cells were chosen as pcdf-NC and pcdf-H, and then they were used for subsequent assays.
Small interfering RNA (siRNA) targeting HOXD-AS1 (siHOXD-AS1#1:
0 ) and nonsilencer (5 0 -AC GUGACACGUUCGGAGAAdTdT-3 0 ) were purchased from RibiBio (RibiBio Co., China). The U251 cell lines were transfected by specific siRNA and cultured for another 48 hr before performing the assay according to the manufacturer's instructions. MiR-130a inhibitor was purchased from RiboBio (RibiBio Co., China).
Cell proliferation assay
Cell proliferation was performed using Cell Counting kit 8 (CCK-8, Dojindo, Japan). Cells from different groups were seeded onto 96-well plates in 100 ll of high-glucose DMEM with 10% FBS at a density of 1,500 cells/well and incubated at 378C. 10 ll of CCK-8 solution was added the wells at the time of 0, 24, 48, 72, 96 and 120 hr after the cells attached to the wells, respectively. The absorbance at 450 nm was measured after the plates were incubated at 378C for 2 hr.
Cell migration and invasion assay
Cell migration and invasion assays were performed using 24-well transwell chambers with 8-lm pore size polycarbonate membranes (BD Biosciences, USA). Cells were plated in transwell chambers without Matrigel for determining cell migration, or in transwell chambers pre-coated with Matrigel (BD Biosciences, USA) for determining the cell invasion ability. Cells in serum-free DMEM were seeded onto the upper chamber, and DMEM supplemented with 10% FBS was added to the lower chambers. After incubation for 24 hr, the nonmigratory or noninvading cells were removed from the upper chamber with a cotton swab, and the cells on the bottom surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Cells in 5 random fields were counted in each well.
Western blotting
Cells were seeded into 6-well plates at a density of 5 3 10 5 cells/well for 48 hr. The cells were then washed in PBS and lysed in ice-cold lysis buffer. The protein contents of the lysates were determined, equal amounts of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then they were transferred onto PVDF membranes (Bio-Rad, USA). Next, nonspecific interactions were blocked by 5% nonfat milk-tris-buffered saline (TBS) with 0.1% Tween-20 and incubated at 378C for 1 hr. Specific antibodies against E2F7/E2F8 (1:500; Proteintech, USA) and b-actin (1:2,000; Sigma, USA) were used to incubate the membranes at 48C for 12 hr to detect the corresponding proteins. The membranes were then washed and incubated with horseradish peroxidase-conjugated secondary antibodies (Bioss Antibodies, Woburn, MA, USA) for 1 hr at 378C. Immunoblots were then detected by enhanced chemiluminescence reagents (Invitrogen Life Technologies) and then they were finally exposed to X-ray films. Quantity One software (Bio-Rad, USA) was used to analyze the relative protein expression levels, with b-actin used as the internal reference.
RNA pull-down assay HOXD-AS1 and its antisense RNAs were labeled using a DIG RNA Labeling Kit (SPT6-T7) and Biotin RNA Labeling Mix (Roche, USA), and they were transcribed with T7 RNA polymerase (Roche, USA) according to the manufacturer's instructions. The plasmids were then linearized and purified using the QIAquick Nucleotide Removal Kit (QIAGEN, USA). Biotinlabeled RNAs and nuclear extracts were mixed with biotinylated RNA containing protease inhibitors and the complexes were incubated with streptavidin agarose beads (Invitrogen, USA) for 1.5 hr. The beads were washed thrice, and the retrieved proteins were subjected to protein identification via mass spectrometry (Laboratory of Fudan University, Shanghai).
Bioinformatics prediction and luciferase reporter assay
The miRanda algorithm was downloaded (http://34.236.212.39/ microrna/getDownloads.do) and the potential miRNAs which could bind with lncRNA HOXD-AS1 were predicted using this algorithm. The miRanda bioinformatics database (http://www. microrna.org/microrna/home.do) was used to search the miR130a binding site in HOXD-AS1 or E2F8. A fragment from XIST containing the predicted miR-130a binding site was amplified by PCR and cloned into a pmirGlO Dual-luciferase miRNA Target Expression Vector (Promega, Madison, WI, USA) to form the reporter vectors, pmirGLO-130a pcdf-H and pmirGLO-130a E2F8. The vectors and the miR-130a mimics were co-transfected, and luciferase activity was measured using the Dual Glo Luciferase Assay System (Promega) following the manufacturer's instructions. The assay was performed in duplicate in three independent experiments.
Statistical analysis
All the experiments were performed in triplicate and all the data were presented as mean 6 standard deviation (SD). Statistical analyses were carried out using SPSS 15.0 statistical software (IBM, SPSS, Chicago, IL). Statistical significance was calculated by Student's t test or one-way ANOVA. p < 0.05 (*) was considered to be statistically significant.
Results

HOXD-AS1 expression is upregulated in glioma cell lines and correlates with glioma grade
To examine the expression level of HOXD-AS1 in the glioma tissues, qRT-PCR was performed in 21 specimens from 
. Effect of HOXD-AS1 on migration and invasion of glioma cells. (a) Relative expression of HOXD-AS1 in U87 cells with HOXD-AS1 overexpression (pcdf-H) or (b) in U251 cells with siRNA targeting HOXD-AS1 (si-H). (c)
In the cell proliferation assay, the absorbance value (450 nm) in the pcdf-H U87 cells and control groups did not significantly differ; (d) similar results were obtained in the si-H U251 cells and si-NC groups. In the cell migration and invasion assays (e) and (g), there were significantly more cells in the pcdf-H group than in the control group in the U87 cells; (f) and (h) there were also significantly more U251 cells in the si-NC group than in the si-H group in the migration assay, and no significant difference was observed between the si-NC group and the si-H group in the U251 cells. Data are presented as mean 6 SD (n 5 3, each group). *p < 0.05 vs. control group. [Color figure can be viewed at wileyonlinelibrary.com] glioma patients. HOXD-AS1 expression was significantly upregulated in the high-grade glioma samples compared to that in the low-grade glioma samples (Fig. 1a) . Similarly, HOXD-AS1 expression was increased dramatically in glioma cell lines U251 when compared with that in the normal glial cells, HA-1800 (Fig. 1b) . Furthermore, we acquired another 17 specimens including normal tissues, low-grade and highgrade glioma tissues to confirm the previous results, and we got the parallel results ( Supporting Information, Fig. S1 ).
HOXD-AS1 has no impact on glioma cell growth
To understand the role of HOXD-AS1 in glioma cell growth, both overexpression and knockdown assays were utilized. Briefly, lentiviruses for HOXD-AS1 overexpression (pcdf-H) and control lentiviruses (pcdf-NC) were used to infect the U87 glioma cells, whose HOXD-AS1 expression was relatively low, whereas specific siRNA against HOXD-AS1 (si-H) and negative control siRNA (si-NC) were used in U251 cells, whose HOXD-AS1 expression was relatively high (Fig. 1b) .
The increased or reduced expression of HOXD-AS1 in these cell lines were confirmed by qRT-PCR (Figs. 2a and 2b) .
Then the CCK-8 assay was performed to determine whether the changes in the level of HOXD-AS1 expression caused any significant change in glioma cell proliferation. Interestingly, there was no significant difference in glioma cell proliferation in the pcdf-H group compared with that in the control group. Similar results were observed in HOXD-AS1 knock-down U251 cells (Figs. 2c and 2d) . Thus, the above results indicate that HOXD-AS1 does not participate in glioma cell proliferation.
HOXD-AS1 promotes glioma cell migration and invasion
By transwell migration assay, we found U87 cells upon HOXD-AS1 overexpression migrated much faster than the control cells whereas the migratory abilities of the U251 cells in the si-H group were significantly impaired compared with those in si-NC group (Figs. 2e and 2f) . A similar effect on cell invasion was observed in parallel invasion assays where the cell invasion potential in the U87 cells was improved in the HOXD-AS1 overexpression group but cell invasion was not obviously inhibited in si-NC group in the U251 cells (Figs. 2g and 2h) . These results indicate that HOXD-AS1 promotes cell migration and invasion in glioma cell lines.
Full-length gene sequence of HOXD-AS1 and its regulation manner
To better characterize HOXD-AS1, 5 0 RACE and 3 0 RACE were used to predict its full sequence. When we inserted the predicted HOXD-AS1 gene into the pGM-T vector, we confirmed that it was 3667 nucleotides long (Fig. 3a) . RNA pull-down results showed that the sense and antisense strands of HOXD-AS1 did not produce different proteins (Fig. 3b) . We then conducted nuclear-cytoplasmic RNA expression analysis by qRT-PCR, and confirmed that HOXD-AS1 was located mainly in the cytoplasm (Fig. 3c) . Thus, our data suggested that HOXD-AS1 could regulate glioma development by binding with miRNA in the ceRNA form (Fig. 3d) . 
HOXD-AS1 regulates transcription factor E2F8 through the miR-130a pathway
Bioinformatics analysis integrating HOXD-AS1, miRNA, and the target genes was conducted to predict the transcription factors that may be influenced by HOXD-AS1 through miRNA. qRT-PCR and Western blotting results indicated that HOXD-AS1 overexpression promoted the upregulation of transcription factors NFYA, E2F8 and E2F7 in pcdf-H U87 cells, while knockdown of HOXD-AS1 inhibited the expression of these transcription factors in si-H U251 cells (Figs. 4a-4d) .
Using the miRanda algorithm, we found that HOXD-AS1 could bind with miR-130a, miR-130b and miR-19. Moreover, using the miRanda database, we found that these miRNAs could bind with transcription factors E2F7 and E2F8. We performed a dual-luciferase reporter assay upon transfection of glioma cells with synthetic miR-130a, miR-130b and miR-19 mimics. Results showed that miR-130a mimics significantly decreased the luciferase activity of HOXD-AS1 compared to the co-transfection of NC mimics, suggesting that HOXD-AS1 could bind with miR-130a (Fig. 4e) . Furthermore, luciferase activity was significantly decreased by the co-transfection of miR-130a mimics and E2F8 rather than by the co-transfection of NC mimics and E2F8, suggesting that E2F8 was the target of miR-130a (Fig. 4f) .
To further identify the interactions between HOXD-AS1, miR-130a and E2F8, we constructed three siRNAs targeting HOXD-AS1 and the most efficient siRNA siHOXD-AS1#3 was selected. Our results found out that in the absence of miR-130 inhibitor, E2F8 was significantly downregulated in si-H U251 cells compared with control HOXD-AS1 cells, while in the presence of miR-130a, downregulation of E2F8 by HOXD-AS1 knockdown was repressed. MiR-130a inhibitor had little influence on HOXD-AS1 downregulation by siRNA (Fig. 4g) .
Above all, these data showed that the triplet HOXD-AS1/ E2F8/miR-130a is involved in a ceRNAs mechanism, and HOXD-AS1 could compete with E2F8 to bind with miR130a, thus affecting the expression of E2F8.
E2F8 reverses the positive effect of HOXD-AS1 on glioma cell migration and invasion
To determine whether the tumor-promoting effects of HOXD-AS1 were mediated by E2F8, we compared the migration and invasion abilities of HOXD-AS1-overexpressing pcdf-H cells transected with siRNA against E2F8 (siE2F8) or control siRNA (si-NC). Transfection efficiency of siRNA against E2F8 was determined by qRT-PCR (Fig. 5a ). The cell migration and invasion abilities of U87 cells were significantly inhibited by si-E2F8 transfection (Figs. 5b and 5c ).
E2F8 inhibits metastasis-related gene expression promoted by HOXD-AS1
Then, we further compared the expression of a panel of metastasis-related genes between HOXD-AS1 overexpression or downregulated glioma cells and their corresponding control cells by qPCR. Results showed that the overexpression of HOXD-AS1 in the U87 cells upregulated the expression of MMP10, TWIST1 and NM23, while knockdown of HOXD-AS1 in the U251 cells downregulated the expression of MMP9, MMP10, TWIST1 and NM23 (Figs. 6a and 6b) . Moreover, knockdown of E2F8 in the pcdf-H U87 cell line significantly downregulated these metastasis-related genes (Fig. 6c) , indicating that si-E2F8 could inhibit the effects of HOXD-AS1 in promoting glioma metastasis (Fig. 6d) .
Discussion
In this study, we found that HOXD-AS1 level was significantly upregulated in glioma cell lines and correlated with glioma grade. Although HOXD-AS1 had no impact on glioma cell growth, it promoted glioma cell migration and invasion. Furthermore, we showed that HOXD-AS1 regulated transcription factor E2F8 through miR-130a pathway.
There is a growing evidence for the involvement of different lncRNAs in oncogenesis and their potential use as cancer biomarkers. 33, 34 Moreover, gliomas of different malignant grades have also been shown to have differential lncRNA expressions. [35] [36] [37] In our study, we found that HOXD-AS1 was significantly upregulated in glioblastoma compared to normal brain tissues and low-grade glioma tissues. Therefore, we hypothesized that HOXD-AS1 participates in glioma progression. We found that HOXD-AS1 promotes glioma cell migration and invasion obviously through a series of functional experiments that examined cell proliferation, migration and invasion.
LncRNAs are potentially implicated in determining glioma development through interaction with different signaling pathways or binding with miRNAs that have a wide range of targets. [38] [39] [40] These in turn allow them to modulate many pathways that are critical to cancer progression, including proliferation, cell death, metastasis, angiogenesis and drug resistance pathways. [41] [42] [43] We performed RNA pull-down and nuclear-cytoplasmic subcellular location assays and demonstrated that HOXD-AS1 was more likely to regulate molecular functions through ceRNA manner. Recently, specific miRNAs-such as miR-23a, miR-145, miR-155 and miR-329-were found to be related with glioma development. [44] [45] [46] [47] In addition, our bioinformatics analysis predicted that HOXD-AS1 could regulate the transcription factors by binding with miR-130a, miR-130b and miR- 19 .
Recent studies have demonstrated that transcription factors were involved in the expression of miRNAs. 48 Transcription factor E2F8, was reported in the progression of several human cancers, such as ovarian, hepatocellular, lung and breast cancers. [49] [50] [51] [52] We performed the luciferase reporter assay to test the binding of miR130a, miR-130b or miR-19 with HOXD-AS1 and E2F8; our results showed that among these miRNAs, miR-130a could simultaneously binds to HOXD-AS1 and E2F8. We further investigated the relationship between HOXD-AS1 and transcription factor E2F8 through functional experiments, and found that HOXD-AS1 positively upregulated E2F8 expression. Meanwhile, knockdown of E2F8 expression using siRNA in HOXD-AS1-overexpressing glioma cells showed that E2F8 significantly inhibited the migration and invasion of HOXD-AS1-overexpressing glioma cells, thus verifying the previous results.
It is initially believed that E2Fs could regulate a diverse number of genes related to cancer metastasis. 53 Our study also detected the differentially expressed genes such as MMP9, MMP10, TWIST1 and NM23 in pcdf-H U87 cells, si-H U251 cells and si-E2F8 U87 cells, where HOXD-AS1 was overexpressed previously by qRT-PCR. We found that the upregulation of HOXD-AS1 could positively regulate the expression of these genes. Thus, upregulation of these genes promote glioma cells migration and invasion.
In conclusion, our study highlights the role for HOXD-AS1 in glioma development and demonstrates the underlying mechanism, leading to the development of a potentially novel strategy for glioma treatment.
Although our study has provided insights into the role of HOXD-AS1 in glioma, a comprehensive study describing its downstream signaling molecules and its prognostic value in clinical glioma patients is warranted.
